December 18, 2020 07:04 AM ESTUpdated 11:59 AM
R&D
Coronavirus

No­var­tis' biotech part­ner ad­mits PhI­II Covid-19 de­feat for stem cell ther­a­py, trig­ger­ing ex­ten­sion of $1.2B+ deal close

Amber Tong

The lat­est cell ther­a­py pro­gram to en­ter No­var­tis’ pipeline has flunked its first Phase III test for ven­ti­la­tor-de­pen­dent Covid-19 pa­tients with mod­er­ate to se­vere acute …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

Roche teams with Flare Ther­a­peu­tics on tran­scrip­tion fac­tors

Neu­ro­gene's stock falls in post-mar­ket trad­ing af­ter ear­ly da­ta in Rett syn­drome

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times